TFF Pharmaceuticals, Inc. (TFFP)

NASDAQ: TFFP · IEX Real-Time Price · USD
5.69
-0.18 (-3.07%)
At close: Jun 24, 2022 4:00 PM
5.68
-0.01 (-0.18%)
After-hours: Jun 24, 2022 5:36 PM EDT
-3.07%
Market Cap 144.38M
Revenue (ttm) 131,281
Net Income (ttm) -31.76M
Shares Out 25.37M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 126,338
Open 5.95
Previous Close 5.87
Day's Range 5.66 - 6.11
52-Week Range 3.60 - 10.70
Beta 2.12
Analysts Buy
Price Target 20.66 (+263.1%)
Earnings Date Aug 11, 2022

About TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation ... [Read more...]

Industry Pharmaceuticals
IPO Date Oct 25, 2019
Employees 4
Stock Exchange NASDAQ
Ticker Symbol TFFP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 20.66, which is an increase of 263.09% from the latest price.

Price Target
$20.66
(263.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference

FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug produc...

TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference

FORT WORTH, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug produc...

Wall Street Analysts Think TFF Pharmaceuticals, Inc. (TFFP) Could Surge 233%: Read This Before Placing a Bet

The mean of analysts' price targets for TFF Pharmaceuticals, Inc. (TFFP) points to a 233.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference

FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug product...

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Techn...

Thin Film Freezing Technology Co-Inventor Dr. Robert O. Williams III to Deliver Platform Presentation of Data on Stabilizing and Delivering Antivirals, Antibodies and Vaccines using Thin Film Freezing T...

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts

TFF Pharmaceuticals, Inc. (TFFP) Reports Q4 Loss, Lags Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -33.33% and 98.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs

TFF Pharma Inks Research Pact With US Army For Dry Powder Medical Countermeasures

TFF Pharmaceuticals Inc (NASDAQ: TFFP) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for defen...

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free ...

New collaboration to study the use of Thin Film Freezing technology to formulate dry powder recombinant vaccine against SARS-CoV-2 for pulmonary delivery New collaboration to study the use of Thin Film ...

TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference

AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products ...

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March...

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

AUSTIN, Texas and SOMERSET, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) and Catalent today announced their collaboration agreement focused on the generation, testin...

TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant

Preclinical studies show that TFF Pharmaceuticals Inc's (NASDAQ: TFFP) inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2. More specifi...

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of ...

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVI...

Complete Safety Data Anticipated by End of 1Q 2022

Recently Revealed Pfizer Collaboration Might Just Be What The Doctor Ordered For TFF Pharmaceuticals

By StoryTrading Pfizer collaboration just revealed in presentation update - no PR issued yet!

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products b...

TFF Pharmaceuticals, Inc. (TFFP) Reports Q3 Loss, Lags Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Mo...

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients